Gliclazide 80mg

Material: Gliclazide 80 mg. Tablets and 30 mg XR Tablet.

Instructions: Type II diabetes mellitus.

Dimensions and Usage Rules: 40-80 mg daily. If needed, gradually increase the level of 320 mg daily Until diabetes comes in control until it can be extended. Gicleade 30-120 mg for X-ray Tablet Seva once a day as per need. X-ray tablets should not be broken or crushed. It should be eaten with Nasta in the morning.

Warnings and in which cases can not be used: In cases of severe diabetes, surgical, wound and infection patients, in diabetic pre-comma and abdominal and severe acupuncture of kidney and liver by juvenile onset diabetes, ketosis and acidsosis.

Side effect: Hypoglycemia may occur in certain conditions. Nausea, appetite depression, diarrhea and constipation, eritema, leucopenia, thrombocytopenia, agranulosi- toosis, pansytopenia, hemolytic anemia, cholestatic joints and hemorrhage in the digestive system etc.

Reactions with other drugs: phenylbutazine, sulfonamide, comerine derivative, beta-blocker, tetracycline, clorromphycle, cofiberate, cementidine, microgenzial, barbiturate, corticosteroid, thyageide diuretic, thyroid hormone, lactative and oral contraceptives.

Use during pregnancy and breastfeeding: Should not be used for mothers during pregnancy and breastfeeding.

āωāĻĒাāĻĻাāύ : āĻ—্āϞিāĻ•াāϜাāχāĻĄ ā§Žā§Ļ āĻŽি.āĻ—্āϰা. āϟ্āϝাāĻŦāϞেāϟ āĻāĻŦং ā§Šā§Ļ āĻŽি.āĻ—্āϰা. āĻāĻ•্āϏ āφāϰ āϟ্āϝাāĻŦāϞেāϟ।

āύিāϰ্āĻĻেāĻļāύা : āϟাāχāĻĒ-⧍ āĻĄাāϝ়াāĻŦেāϟিāϏ āĻŽেāϞিāϟাāϏ।

āĻŽাāϤ্āϰা āĻ“ āĻŦ্āϝāĻŦāĻšাāϰ āĻŦিāϧি : āĻĻৈāύিāĻ• ā§Ēā§Ļ-ā§Žā§Ļ āĻŽি.āĻ—্āϰা.। āĻĒ্āϰāϝ়োāϜāύে āϧীāϰে āϧীāϰে āĻŽাāϤ্āϰা āĻĻৈāύিāĻ• ā§Šā§¨ā§Ļ āĻŽি.āĻ—্āϰা. āĻĒāϰ্āϝāύ্āϤ āĻŦৃāĻĻ্āϧি āĻ•āϰা āϝেāϤে āĻĒাāϰে āϝāϤāĻĻিāύ āύা āĻĄাāϝ়াāĻŦেāϟিāϏ āύিāϝ়āύ্āϤ্āϰāĻŖে āφāϏে। āĻāĻ•্āϏ āφāϰ āϟ্āϝাāĻŦāϞেāϟেāϰ āĻ•্āώেāϤ্āϰে āĻ—িāĻ•াāϜাāχāĻĄ ā§Šā§Ļ-⧧⧍ā§Ļ āĻŽি.āĻ—্āϰা. āĻĒ্āϰāϝ়োāϜāύ āĻ…āύুāϝাāϝ়ী āĻĻিāύে āĻāĻ•āĻŦাāϰ āϏেāĻŦ্āϝ। āĻāĻ•্āϏ āφāϰ āϟ্āϝাāĻŦāϞেāϟ āĻ­েāĻ™্āĻ—ে āĻŦা āϚুāώে āĻ–াāĻ“āϝ়া āωāϚিāϤ āύāϝ়। āϏāĻ•াāϞে āύাāϏāϤ্āĻŽাāϰ āϏাāĻĨে āĻ–াāĻ“āϝ়া āωāϚিāϤ।

āϏāϤāϰ্āĻ•āϤা āĻ“ āϝেāϏāĻŦ āĻ•্āώেāϤ্āϰে āĻŦ্āϝāĻŦāĻšাāϰ āĻ•āϰা āϝাāĻŦে āύা : āϜুāĻ­েāύাāχāϞ āĻ…āύāϏেāϟ āĻĄাāϝ়াāĻŦেāϟিāϏে, āĻ•িāϟোāϏিāϏ্‌ āĻāĻŦং āĻāϏিāĻĄোāϏিāϏ্‌ āĻĻ্āĻŦাāϰা āϜāϟিāϞ āĻĄাāϝ়াāĻŦেāϟিāϏে, āĻ…āϏ্āϤ্āϰোāĻĒāϚাāϰ, āĻ•্āώāϤ āĻāĻŦং āϏংāĻ•্āϰāĻŽāĻŖেāϰ āϰোāĻ—ীāĻĻেāϰ āĻ•্āώেāϤ্āϰে, āĻĄাāϝ়াāĻŦেāϟিāĻ• āĻĒ্āϰি-āĻ•āĻŽা āĻāĻŦং āĻ•āĻŽাāϰ āĻ•্āώেāϤ্āϰে āĻāĻŦং āĻŦৃāĻ•্āĻ• āĻ“ āϝāĻ•ৃāϤেāϰ āϤীāĻŦ্āϰ āĻ…āĻĒāϰ্āϝাāĻĒ্āϤāϤাāϝ়।

āĻĒাāϰ্āĻļ্āĻŦ āĻĒ্āϰāϤিāĻ•্āϰিāϝ়া : āĻ•িāĻ›ু āĻ•িāĻ›ু āĻŦিāĻļেāώ āĻ…āĻŦāϏ্āĻĨাāϝ় āĻšাāχāĻĒোāĻ—্āϞাāχāϏেāĻŽিāϝ়া āĻšāϤে āĻĒাāϰে। āĻŦāĻŽি āĻŦāĻŽি āĻ­াāĻŦ,āĻ•্āώুāϧা āĻŽāύ্āĻĻা, āĻĄাāϝ়āϰিāϝ়া āĻāĻŦং āĻ•োāώ্āĻ āĻ•াāĻ িāύ্āϝ, āχāϰিāĻĨেāĻŽা, āϞিāωāĻ•োāĻĒেāύিāϝ়া, āĻĨ্āϰāĻŽ্āĻŦোāϏাāχāϟোāĻĒেāύিāϝ়া, āĻāĻ—্āϰাāύুāϞোāϏাāχ- āϟোāϏিāϏ, āĻĒ্āϝাāύāϏাāχāϟোāĻĒেāύিāϝ়া, āĻšিāĻŽোāϞাāχāϟিāĻ• āĻāύেāĻŽিāϝ়া, āĻ•োāϞেāϏ্āϟ্āϝাāϟিāĻ• āϜāĻŖ্āĻĄিāϏ āĻāĻŦং āĻĒāϰিāĻĒাāĻ•āύাāϞীāϰ āĻšেāĻŽোāϰেāϜ āχāϤ্āϝাāĻĻি।

āĻ…āύ্āϝ āĻ“āώুāϧেāϰ āϏাāĻĨে āĻĒ্āϰāϤিāĻ•্āϰিāϝ়া : āĻĢিāύাāχāϞāĻŦিāωāϟাāϜোāύ, āϏাāϞāĻĢোāύাāĻŽাāχāĻĄ, āĻ•োāĻŽাāϰিāύ āĻĄেāϰিāĻ­েāϟিāĻ­, āĻŦিāϟা- āĻŦ্āϞāĻ•াāϰ, āϟেāϟ্āϰাāϏাāχāĻ•্āϞিāύ, āĻ•্āϞোāϰাāĻŽāĻĢেāύিāĻ•āϞ, āĻ•োāĻĢাāχāĻŦ্āϰেāϟ, āϏিāĻŽেāϟিāĻĄিāύ, āĻŽাāχāĻ•োāύাāϜāϞ, āĻŦাāϰāĻŦিāϚুāϰেāϟ, āĻ•āϰ্āϟিāĻ•োāώ্āϟেāϰāϝ়েāĻĄ, āĻĨাāϝ়াāϜাāχāĻĄ āĻĄাāχāχāωāϰেāϟিāĻ•, āĻĨাāχāϰāϝ়েāĻĄ āĻšāϰāĻŽোāύ, āϞ্āϝাāĻ•্āϏাāϟিāĻ­ āĻāĻŦং āĻŽুāĻ–ে āϏেāĻŦ্āϝ āϜāύ্āĻŽāύিāϰোāϧāĻ• āϏāĻŽূāĻš।

āĻ—āϰ্āĻ­াāĻŦāϏ্āĻĨা āĻ“ āϏ্āϤāύ্āϝāĻĻাāύāĻ•াāϞে āĻŦ্āϝāĻŦāĻšাāϰ : āĻ—āϰ্āĻ­াāĻŦāϏ্āĻĨাāϝ় āĻ“ āϏ্āϤāύ্āϝāĻĻাāύāĻ•াāϞীāύ āĻŽাāϝ়েāĻĻেāϰ āĻ•্āώেāϤ্āϰে āĻŦ্āϝāĻŦāĻšাāϰ āĻ•āϰা āωāϚিāϤ āύāϝ়।

Post a Comment

Previous Next

Ų†Ų…ŲˆØ°ØŦ Ø§Ų„Ø§ØĒØĩØ§Ų„